This application proposes to establish an international, multi-centered consortium with sites in Goteborg Sweden, Milan Italy, San Francisco USA, and Sydney Australia to advance the rational use of cerebrospinal fluid (CSF) molecular markers to manage (prevent, diagnose and treat) and understand the pathogenesis of HIV-1 brain infection and its major clinical consequence, the AIDS dementia complex (ADC). The requested funding will be used to: 1. Develop the infrastructure, methodologies and procedures of the cooperative consortium that facilitate a sequential, more expeditious approach to analysis of CSF changes in HIV infection that could be accomplished by a single institution; 2. Carry out initial screening of a preliminary group of candidate CSF markers, with components assessing virological, host immunological, neural and blood-brain barrier contributions to CSF composition, and to reduce this to a smaller initial core CSF marker battery using a matrix of about 160 well-defined, cross-sectional CSF and blood sample pairs; 3. Further assess and refine this battery into a well-characterized secondary core CSF marker battery by additional (a) cross-sectional study to test the diagnostic value of the individual and combined markers with a more complex, real-world spectrum of samples and patients and (b) short-term longitudinal studies of marker dynamics after initiation of cessation of anti-retroviral therapy; 4. Continue to enlarge to enlarge CSF/plasma sample repositories and to assess additional markers as candidates to add to or replace component markers of the secondary battery and to address questions of pathogenesis; 5. Develop formal models of individual marker dynamics and their interactions; 6. Use the information derived from these studies to formulate a set of CSF marker guidelines for the design of clinical trials. Additionally, throughout the 5 years of this study, measures will be taken to prepare for and subsequently extend this study through integration with studies using other modalities, including functional neuroimaging and genetic analyses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS043103-05
Application #
7011174
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Wong, May
Project Start
2002-02-15
Project End
2008-01-31
Budget Start
2006-02-01
Budget End
2008-01-31
Support Year
5
Fiscal Year
2006
Total Cost
$259,629
Indirect Cost
Name
University of California San Francisco
Department
Neurology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Suh, Joome; Sinclair, Elizabeth; Peterson, Julia et al. (2014) Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection. J Neuroinflammation 11:199
Grund, Birgit; Wright, Edwina J; Brew, Bruce J et al. (2013) Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. J Neurovirol 19:383-92
Peluso, Michael J; Meyerhoff, Dieter J; Price, Richard W et al. (2013) Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 207:1703-12
Peluso, Michael J; Ferretti, Francesca; Peterson, Julia et al. (2012) Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 26:1765-74
Spudich, Serena; Gisslen, Magnus; Hagberg, Lars et al. (2011) Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 204:753-60
Brew, Bruce J; Cysique, Lucette A (2010) Alzheimer disease and HIV: a tangled story. Neurology 75:105-6
Gisslen, Magnus; Krut, Jan; Andreasson, Ulf et al. (2009) Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 9:63
Karlsson, Ulf; Antonsson, Liselotte; Repits, Johanna et al. (2009) Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates. AIDS Res Hum Retroviruses 25:1297-1305
Bergroth, T; Ekici, H; Gisslen, M et al. (2009) Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma. HIV Med 10:111-5
Abdulle, Sahra; Hagberg, Lars; Svennerholm, Bo et al. (2008) Cerebrospinal fluid viral load and intrathecal immune activation in individuals infected with different HIV-1 genetic subtypes. PLoS One 3:e1971

Showing the most recent 10 out of 36 publications